IMMUNE MEDIATED SIDE EFFECTS OF PEMBROLIZUMAB AND NIVOLUMAB THERAPY: PATHOPHYSIOLOGY, GENETIC CONTRIBUTIONS AND CLINICAL SIGNIFICANCE
Karamello Halak, Yuseph Mohamed, Armantas Gintautas Abstract Pembrolizumab and nivolumab are examples of immune checkpoint inhibitors (ICIs) drugs that are cancer treating drugs that reactivate antitumor immune responses. But they result in immune related side effects (irAEs) that are typically multisystemic and unpredictable. In additionally referring to advanced artificial intelligence (machine learning) for early detection…